List view / Grid view
The new industry collaboration aims to help decarbonise the global supply chain by focusing on the energy-intensive pharmaceutical manufacturing that takes place in China and India.
PARP inhibitor olaparib has been recommended in NICE’s final draft guidance for early breast cancer and advanced prostate cancer.
The roadmap clarifies the processes to develop advanced therapy medicinal products (ATMPs), providing guidance on key considerations.
![Researcher looking at an experiment [Credit: Unsplash].](https://www.europeanpharmaceuticalreview.com/wp-content/uploads/Bell-advanced-therapies-feature-300x278.jpg)
![Researcher looking at an experiment [Credit: Unsplash].](https://www.europeanpharmaceuticalreview.com/wp-content/uploads/Bell-advanced-therapies-feature.jpg)
Advanced therapies are a ground-breaking new class of medicines that use gene therapy, cell therapy or tissue engineering to treat disease and injury. Rachel Bell, Trainee Patent Attorney at Marks & Clerk, and Ceri Roberts, Scientific Training Manager – Cellular and Molecular Therapies at NHS Blood and Transplant, discuss some…
New guidance on the licensing of biosimilar products that reduces unnecessary clinical trials is expected to put the UK ahead of Europe and facilitate a boom in these essential life-saving medicines, creating greater patient access and saving the National Health Service (NHS) hundreds of millions of pounds. It could also…
Tagrisso (osimertinib) was approved for an indication extension after it reduced risk of death by over 80 percent in certain early-stage non-small cell lung cancer patients.
The European Commission and European Medicines Agency have approved the triple combination Kaftrio for use in certain cystic fibrosis patients, triggering the drug to be accessible on the UK’s National Health Service.
A new agreement will allow eligible cystic fibrosis patients in England to have access to CFTR modulators to treat the underlying cause of their disease.
The NHS is set to launch a new payment method for antibiotic development to incentivise pharmaceutical companies.
A CAR-T immunotherapy for adults with an aggressive form of non-Hodgkin lymphoma has been provisionally rejected by the NHS...
NHS England has announced a commercial agreement that allows patients in England immediate access to the innovative new multiple sclerosis treatment...
NICE has recommended sorafenib to be routinely available for patients on the NHS making it one of the 24 drugs appraised from the CDF...
A new deal on the breast cancer drug trastuzumab emtansine means that it can now be recommended for routine funding.
Olaratumab is the first monoclonal antibody, in combination with doxorubicin, to be recommended for the treatment of advanced soft tissue sarcoma.
3 January 2017 | By Niamh Louise Marriott, Digital Editor
Surgeons at Manchester and Moorfields Eye Hospital made history by delivering the world’s first trial of the Argus II Bionic Eye implants in RP...
